Abstract:The importance of ordering drugs from online pharmacies in Germany is increasing constantly. At the same time, there are many online pharmacies that try to increase their own market share through advertising. In Germany, the advertising of drugs is regulated by the Therapeutic Products Advertising Act (Heilmittelwerbegesetz (HWG)) and must therefore also be complied with by online pharmacies in their product catalogues. One important purpose of the HWG is to protect consumers by ensuring that they are presented with all necessary medical-pharmacological information about the advertised product. This paper examines the implementation of as well as the compliance with Section 4 of the HWG in the product catalogues of two online pharmacies. For this purpose, the spring/summer catalogue of 2023 was considered in the allergy, cold and gastrointestinal tract categories, resulting in the inclusion of 143 drugs from online pharmacy 1 (OP1) and 102 drugs from online pharmacy 2 (OP2) for the analysis. The information on the drugs was taken from the respective catalogue and the pharmaceutical index 'Gelbe Liste', collected in tabular form and was encoded. Subsequently, the required mandatory information according to Section 4 was checked by comparing the collected information with the information from the package leaflet. The analysis revealed that both catalogues insufficiently complied with Section 4 of the HWG. OP1 complied with 75% of the mandatory information required under Section 4 of the HWG and OP2 with 64%. In the OP1 catalogue, there is no indication for 6% of the drugs and no specification for 29% of the traditionally registered drugs. In addition, the mandatory notice on risks and adverse effects in the OP1 catalogue is not presented in a consumer-friendly way. In the OP2 catalogue, further concerns about the compliance with the HWG were raised due to the missing indication for 17% of the drugs, no warning for 64% of the ethanol-containing drugs and no active ingredient for 31% of the monopreparations. The insufficient compliance with the HWG in the product catalogues of OP1 and OP2 means that consumer protection as a stated objective of the HWG cannot be guaranteed. Advertising for drugs should only be possible under the condition that the content of the advertisement complies with the HWG. Insufficient compliance, as in the product catalogue of OP1 and OP2, should be prohibited as it directly contradicts the law's objective.

[Bottlenecks in the availability of ophthalmological medications : Initiative of the Working Group on Ethics in Ophthalmology of the DOG and the University Eye Clinic Bonn]

Reasons for supply side driven drug shortages - A mixed-methods study on first-level, higher-level, and root causes from the perspective of marketing authorization holders

Ensuring availability of respiratory medicines in times of European drug shortages

Proposal for Handling of Medicine Shortages Based on a Comparison of Retrospective Risk Analysis

A Qualitative Approach to a Better Understanding of the Problems Underlying Drug Shortages, as Viewed from Belgian, French and the European Union’s Perspectives

Trends of use of drugs with suggested shortages and their alternatives across 52 real world data sources and 18 countries in Europe and North America

Insufficient compliance of the German Therapeutic Products Advertising Act in product catalogues of online pharmacies

Drug shortage management: A qualitative assessment of a collaborative approach

Novel Drug Delivery Systems Fighting Glaucoma: Formulation Obstacles and Solutions

Can't prescribe, can't dispense: the challenge of medicine shortages

Medicine shortages: a commentary on causes and mitigation strategies

Prevention and management of health products shortages by the French national agency (ANSM), 10 years of experience

Ethical conflicts in patient care situations of community pharmacists: a cross-sectional online survey

Advancements in Ocular Therapy: A Review of Emerging Drug Delivery Approaches and Pharmaceutical Technologies

The French reporting system for drug shortages: description and trends from 2012 to 2018: an observational retrospective study

Tackling medicine shortages during and after the COVID-19 pandemic: Compilation of governmental policy measures and developments in 38 countries

Shortage of perioperative supplies and drugs: Theory and practical implications

Toward a European definition for a drug shortage: a qualitative study

Pharmacists' approach to oncology medicine shortages: results of a cross-sectional survey in Pakistan

Results of health technology assessments of orphan drugs in Germany—lack of added benefit, evidence gaps, and persisting unmet medical needs

[Medication supply and polypharmacy in long-term care : An overview of possible interventions and the question of a functioning concept]